Xu Kunlin was still hesitant.
"President Xie, I think this plan is too risky."
"While it's true that our new drug, Sorafenib, has shown significant efficacy in treating late-stage liver cancer, we still saw a lot of toxic side effects during the preliminary verification stage."
"So far, my research has cataloged the following: circulatory system side effects like increased blood pressure, subungual linear hemorrhages, cerebrovascular accidents, and thrombotic diseases; adverse skin reactions like hand-foot syndrome and facial erythema; diarrhea; adverse reactions in the hematopoietic system; and so on. There's also a chance it could lead to hepatobiliary system abnormalities and increase the risk of bleeding…"
"While some side effects can be mitigated or eliminated through dosage control and corresponding symptomatic treatments, we still can't completely avoid severe adverse reactions…"
